Sep 1, 2026 09:07AM
Apr 20, 2026 07:02AM
Apr 20, 2026 07:00AM
Dec 21, 2025 04:00AM
Jun 10, 2025 07:00AM
Jun 10, 2025 07:00AM
May 8, 2025 07:00AM Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
Apr 28, 2025 07:05AM
Apr 28, 2025 07:00AM
Mar 20, 2025 07:00AM
Jan 10, 2025 07:05AM
Jan 10, 2025 07:00AM
Dec 11, 2024 07:02AM
Dec 11, 2024 07:00AM Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer Symposium on the Potential of its CDK2-directed Molecular Glue Degraders to Treat HR-positive/HER2-negative Brea
Nov 7, 2024 07:00AM
Aug 8, 2024 07:00AM
Jun 28, 2024 10:41AM
Jun 27, 2024 07:06AM
Jun 27, 2024 07:00AM
Jun 14, 2024 08:46AM
Jun 14, 2024 08:45AM Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
May 21, 2024 07:00AM
May 9, 2024 07:00AM
Mar 14, 2024 07:00AM
Mar 11, 2024 07:04AM
Mar 11, 2024 07:00AM
Jan 8, 2024 07:19AM
Jan 8, 2024 07:15AM Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Nov 9, 2023 07:00AM
Aug 10, 2023 07:15AM
Mar 16, 2023 07:30AM
Jan 9, 2023 07:30AM
Nov 10, 2022 07:30AM
Sep 6, 2022 07:33AM
Sep 6, 2022 07:30AM Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader
Aug 11, 2022 07:30AM
May 11, 2022 07:30AM
Mar 29, 2022 07:30AM
Nov 10, 2021 07:30AM

329,914 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All